termsTerm
Differentiation syndrome
When a targeted drug makes leukaemia cells mature all at once, causing fever, fluid in the lungs, and weight gain. Treatable with steroids if caught early.
First described with ATRA in APL; now a boxed-warning class effect of IDH inhibitors (ivosidenib, enasidenib, olutasidenib) and menin inhibitors (revumenib, ziftomenib), occurring in roughly 10-25%. Managed with dexamethasone, hydroxyurea for leukocytosis, and dose interruption.
Toxicity: what this kind of term is about · animated schematic, not to scale
Category
Toxicity
cancers
2targets
2drugs
8Not mapped hereInorganic arsenical (differentiation agent)
Arsenic trioxide · Trisenox
ApprovedSmall-molecule IDH2 inhibitor
Enasidenib · Idhifa
ApprovedSmall-molecule kinase inhibitor (FLT3, type I)
Gilteritinib · Xospata
ApprovedSmall-molecule IDH1 inhibitor
Ivosidenib · Tibsovo
ApprovedSmall-molecule IDH1 inhibitor
Olutasidenib · Rezlidhia
ApprovedSmall-molecule menin inhibitor
Revumenib · Revuforj
Not mapped hereOral retinoid (differentiation agent)
Tretinoin (all-trans retinoic acid, ATRA) · Vesanoid
ApprovedSmall-molecule menin inhibitor
Ziftomenib · Komzifti